コンテンツへスキップ
Merck
  • HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer.

HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer.

Cell reports (2020-05-14)
Holly Brunton, Giuseppina Caligiuri, Richard Cunningham, Rosie Upstill-Goddard, Ulla-Maja Bailey, Ian M Garner, Craig Nourse, Stephan Dreyer, Marc Jones, Kim Moran-Jones, Derek W Wright, Viola Paulus-Hock, Colin Nixon, Gemma Thomson, Nigel B Jamieson, Grant A McGregor, Lisa Evers, Colin J McKay, Aditi Gulati, Rachel Brough, Ilirjana Bajrami, Stephen J Pettitt, Michele L Dziubinski, Simon T Barry, Robert Grützmann, Robert Brown, Edward Curry, Marina Pajic, Elizabeth A Musgrove, Gloria M Petersen, Emma Shanks, Alan Ashworth, Howard C Crawford, Diane M Simeone, Fieke E M Froeling, Christopher J Lord, Debabrata Mukhopadhyay, Christian Pilarsky, Sean E Grimmond, Jennifer P Morton, Owen J Sansom, David K Chang, Peter J Bailey, Andrew V Biankin
要旨

Pancreatic ductal adenocarcinoma (PDAC) can be divided into transcriptomic subtypes with two broad lineages referred to as classical (pancreatic) and squamous. We find that these two subtypes are driven by distinct metabolic phenotypes. Loss of genes that drive endodermal lineage specification, HNF4A and GATA6, switch metabolic profiles from classical (pancreatic) to predominantly squamous, with glycogen synthase kinase 3 beta (GSK3β) a key regulator of glycolysis. Pharmacological inhibition of GSK3β results in selective sensitivity in the squamous subtype; however, a subset of these squamous patient-derived cell lines (PDCLs) acquires rapid drug tolerance. Using chromatin accessibility maps, we demonstrate that the squamous subtype can be further classified using chromatin accessibility to predict responsiveness and tolerance to GSK3β inhibitors. Our findings demonstrate that distinct patterns of chromatin accessibility can be used to identify patient subgroups that are indistinguishable by gene expression profiles, highlighting the utility of chromatin-based biomarkers for patient selection in the treatment of PDAC.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
アンチマイシンA 放線菌由来
Sigma-Aldrich
ヒドロコルチゾン, BioReagent, suitable for cell culture
Sigma-Aldrich
2-デオキシ-D-グルコース, ≥98% (GC), crystalline
Sigma-Aldrich
アポトランスフェリン ヒト, powder, BioReagent, suitable for cell culture, ≥98% (agarose gel electrophoresis)
Sigma-Aldrich
ロテノン, ≥95%
Sigma-Aldrich
3,3′,5-トリヨード-L-チロニン ナトリウム塩, powder, BioReagent, suitable for cell culture
Sigma-Aldrich
L-カルニチン 塩酸塩, synthetic, ≥98%
Sigma-Aldrich
オリゴマイシン Streptomyces diastatochromogenes由来, ≥90% total oligomycins basis (HPLC)
Sigma-Aldrich
カルボニルシアニド 3-クロロフェニルヒドラゾン, ≥97% (TLC), powder
Sigma-Aldrich
フェナジンメトスルファート
Sigma-Aldrich
O-ホスホリルエタノールアミン
Sigma-Aldrich
(+)-エトモキシル ナトリウム塩 水和物, ≥98% (HPLC), powder
Millipore
Millex PVDFシリンジフィルター, pore size 0.45 μm, diam. 4 mm, sterile, hydrophilic
Sigma-Aldrich
ウシ血清アルブミン ウシ血清由来, heat shock fraction, pH 7, ≥98%
Sigma-Aldrich
6-アミノニコチンアミド, 99%
Sigma-Aldrich
MISSION® esiRNA, targeting human HNF4A
Sigma-Aldrich
MISSION® esiRNA, targeting human PLK1
Sigma-Aldrich
MISSION® esiRNA, targeting human GATA6